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Background: Ranpirnase (Rap) is an amphibian ribonuclease with reported antitumor activity, minimal toxicity, and
negligible immunogenicity in clinical studies, but the unfavorable pharmacokinetics and suboptimal efficacy hampered
its further clinical development. To improve the potential of Rap-based therapeutics, we have used the DOCK-AND-
LOCK™ (DNL™) method to construct a class of novel IgG-Rap immunoRNases. In the present study, a pair of these
constructs, (Rap)2-E1-(Rap)2 and (Rap)2-E1*-(Rap)2, comprising four copies of Rap linked to the CH3 and CK termini of hRS7
(humanized anti-Trop-2), respectively, were evaluated as potential therapeutics for triple-negative breast cancer (TNBC).
Methods: The DNL-based immunoRNases, (Rap)2-E1-(Rap)2 and (Rap)2-E1*-(Rap)2, were characterized and tested for
biological activities in vitro on a panel of breast cancer cell lines and in vivo in a MDA-MB-468 xenograft model.
Results: (Rap)2-E1-(Rap)2 was highly purified (>95%), exhibited specific cell binding and rapid internalization in MDA-MB-
468, a Trop-2-expressing TNBC line, and displayed potent in vitro cytotoxicity (EC50≤ 1 nM) against diverse breast cancer
cell lines with moderate to high expression of Trop-2, including MDA-MB-468, BT-20, HCC1806, SKBR-3, and MCF-7. In
comparison, structural counterparts of (Rap)2-E1-(Rap)2, generated by substituting hRS7 with selective non-Trop-2-binding
antibodies, such as epratuzumab (anti-CD22), were at least 50-fold less potent than (Rap)2-E1-(Rap)2 in MDA-MB-468 and
BT-20 cells, both lacking the expression of the cognate antigen. Moreover, (Rap)2-E1-(Rap)2 was less effective (EC50 > 50 nM)
in MDA-MB-231 (low Trop-2) or HCC1395 (no Trop-2), and did not show any toxicity to human peripheral blood
mononuclear cells. In a mouse TNBC model, a significant survival benefit was achieved with (Rap)2-E1*-(Rap)2 when
given the maximal tolerated dose.
Conclusions: A new class of immunoRNases was generated with enhanced potency for targeted therapy of cancer.
The promising results from (Rap)2-E1-(Rap)2 and (Rap)2-E1*-(Rap)2 support their further investigation as a potential
treatment option for TNBC and other Trop-2-expressing cancers.
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Breast cancer is the leading cause of cancer deaths in
women and the second most common cancer worldwide
after lung cancer [1]. In the USA, about 232,340 new
cases of this cancer will be diagnosed and about 39,620
women will die from this disease in 2013 [2]. During the
past two decades, important advances have been made* Correspondence: dliu@immunomedics.com; dmg.gscancer@att.net
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[3,4] and human epidermal growth factor receptor type
2 (HER2)-overexpressing breast cancers [5,6]. However,
effective therapies for patients with triple-negative breast
cancer (TNBC), which lacks the expression of estrogen
receptor (ER), progesterone receptor (PR) and HER2, are
still urgently needed [7]. TNBC, afflicting approximately
12 to 17% of women with breast cancer [8], is a hetero-
geneous disease with varying prognoses according to
molecular, pathological, and clinical factors [9,10]. Be-
cause of the absence of clear targets like HER2, ER, andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 DNL-Rap conjugates used in the study
Code Target AD2-module DDD2-module
(Rap)2-E1-(Rap)2 Trop-2 CH3-AD2-IgG-hRS7 Rap-DDD2
(Rap)2-22-(Rap)2 CD22 CH3-AD2-IgG-hLL2 Rap-DDD2
(Rap)2-20-(Rap)2 CD20 CH3-AD2-IgG-hA20 Rap-DDD2
(Rap)2-74-(Rap)2 CD74 CH3-AD2-IgG-hLL1 Rap-DDD2
(Rap)2-C2–(Rap)2 HLA-DR CH3-AD2-IgG-hL243 Rap-DDD2
(Rap)2-14-(Rap)2 CEACAM5 CH3-AD2-IgG-hMN-14 Rap-DDD2
(Rap)2-E1*-(Rap)2 Trop-2 CK-−AD2-IgG-hRS7 Rap-DDD2
(Rap)2-22*-(Rap)2 CD22 CK-AD2-IgG-hLL2 Rap-DDD2
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mide followed by paclitaxel is recommended as the
standard of care for systemic treatment of TNBC in the
adjuvant setting [11], whereas for patients with meta-
static disease, there is no standard first-line agent. To
date, various approved agents, including platinum-based
compounds, ixabepilone, erlotinib, bevacizumab, cetuxi-
mab, and several investigative drugs, in particular, inhibi-
tors of PARP, tyrosine kinases, or mTOR, are being
evaluated alone or in combination in different phases of
clinical development for TNBC [11]. An arduous chal-
lenge in TNBC chemotherapy is primary or acquired
drug resistance, resulting in incomplete response, relapse
and poor survival.
Rap is a single-chain protein of 104 amino acids (MW
~12 kDa) originally isolated from the oocytes of Rana
pipiens, a Northern leopard frog [12]. Rap exhibits cyto-
static and cytotoxic effects on a variety of tumor cell
lines in vitro [13], as well as antitumor activity in vivo
[14]. The amphibian ribonuclease enters cells via AP-2/
clathrin-mediated endocytosis [15] and once internalized
into the cytosol, it selectively degrades tRNA [16],
thereby inhibiting protein synthesis and inducing apop-
tosis [17]. In addition, Rap was shown to enhance both
the in vitro and in vivo antitumor activity of vincristine
against HT-29 human colorectal cancer cells that had
been rendered multidrug-resistant by overexpressing the
mdr1 gene [18], and induce caspase-independent cell
death in both drug-sensitive and -resistant neuroblast-
oma cells and tumor xenografts [19]. Clinical studies of
Rap in patients with unresectable malignant mesotheli-
oma showed a significant impact on the survival of pa-
tients treated with doxorubicin plus Rap compared to
doxorubicin alone [20], and a dose-limiting renal toxicity
that was reversible upon discontinuation of treatment
[21]. Notably, an earlier Phase I trial of Rap in patients
with solid cancers reported a lack of untoward immune
response upon repeated weekly injections [22].
Trop-2, also known as EGP-1 (epithelial glycoprotein-
1), is a cell-surface glycoprotein overexpressed by a variety
of epithelial carcinomas relative to corresponding normal
tissues [23]. The expression of Trop-2 was shown to be
necessary for tumorigenesis and invasiveness of colon can-
cer cells, which could be reduced effectively with a poly-
clonal antibody against the extracellular domain of Trop-2
[24]. More recently, the biological function of Trop-2 in
promoting self-renewal and hyperplasia in the prostate
was attributed to the accumulation in the nucleus of the
intracellular domain of Trop-2 following its cleavage via
regulated intramembrane proteolysis [25]. Because of the
well-documented clinical evidence in breast cancer [26],
colorectal cancer [27,28] and other cancers [29] that over-
expressed Trop-2 is associated with increased tumor ag-
gressiveness, metastasis, and decreased patient survival,there is a growing interest in Trop-2 as a therapeutic target
for solid cancers [30]. For example, the humanized anti-
Trop-2 monoclonal antibody (mAb), hRS7, is currently
under clinical investigation as a drug delivery moiety for
patients with advanced epithelial cancers (NCT01631552).
The DOCK-AND-LOCK™ (DNL™) method [31-33] is a
platform technology for production of multivalent,
multifunctional conjugates by utilizing the naturally oc-
curring interaction between the dimerization and dock-
ing domain (DDD) of cAMP-dependent protein kinase
A (PKA) and the anchoring domain (AD) of an A-kinase
anchoring protein (AKAP). The established strategy in-
volves the use of a specific pair of DDD and AD pep-
tides, termed DDD2 and AD2, to generate two distinct
modules, which upon mixing under redox conditions,
self-assemble into a DNL conjugate with retained activ-
ity and defined composition. We previously reported the
antitumor activity of a novel immunotoxin, designated
Rap(Q)-hRS7, in Trop-2-expressing cancer cells [34].
The recombinantly-produced Rap(Q)-hRS7 comprises
two molecules of Rap(p.N69Q) or N69Q-Rap, a variant
of Rap with the putative N-glycosylation site removed by
replacing the 69th residue of asparagine (N69) with glu-
tamine (Q), each fused to a light chain of hRS7 at the
amino terminus [34].
To further explore the potential of Rap-based immu-
notoxins, we applied the DNL method to site-specifically
tether a dimerized Rap, denoted as (Rap)2, where (Rap)
represents Rap-DDD2, at each of the carboxyl termini of
either the heavy chain (the CH3–format) or the light
chain (the CK-format) of a humanized IgG, resulting in a
class of novel immunoconjugates (Table 1) with tetrakis
Rap (Figure 1). As exemplified herein by (Rap)2-E1-
(Rap)2, comprising four copies of Rap linked to the
AD2-fused CH3 termini of hRS7 IgG (denoted as E1),
and by (Rap)2-E1*-(Rap)2, comprising four copies of Rap
linked to the AD2-fused CK termini of hRS7 IgG (de-
noted as E1*), these DNL-based immunoRNases could
offer a distinct advantage over their recombinantly-
produced fusion counterparts, such as Rap(Q)-hRS7, in
Figure 1 Schematic of expression cassettes and cartoon structures of CH3-AD2-IgG (or X), Ck3-AD2-IgG (or X*), Rap-DDD2, (Rap)2,
(Rap)2-X-(Rap)2, and (Rap)2-X*-(Rap)2. DDD2 and AD2 are shown in blue and red, respectively. SH, V, C, G, L, and 6H represent sulfhydryl
groups, variable domain (green), constant region (gray), hinge, linker (GSGGGGSGG), and His tag (HHHHHH), respectively.
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and tumor xenografts in vivo.
Results
Preparation and characterization of DNL-Rap conjugates
Each DNL-Rap conjugate (Table 1) was obtained with a
general protocol involving (i) expression of the respect-
ive IgG-AD2 module in myeloma cells, with purification
by protein A-based MabSelect affinity chromatography;
(ii) expression of Rap-DDD2 in E. coli as inclusion bod-
ies, purified by immobilized metal affinity chromatog-
raphy under denaturing conditions, and subsequently
refolded; (iii) combination of IgG-AD2 with Rap-DDD2
under redox conditions; and (iv) purification of the
resulting DNL-Rap conjugate by MabSelect chromatog-
raphy. Representative results on the SDS-PAGE, size
exclusion high-performance liquid chromatography (SE-
HPLC) and dynamic light scattering analyses demon-
strating the molecular purity and integrity of DNL-Rap
conjugates are shown for (Rap)2-E1-(Rap)2, (Rap)2-E1*-
(Rap)2, (Rap)2-22-(Rap)2, and (Rap)2-22*-(Rap)2 (Additional
file 1: Figure S1A-E), and summarized below. On non-
reducing gel, (Rap)2-E1-(Rap)2 was detected as a predom-
inant band (Additional file 1: Figure S1A; lane 6) having
the expected size between the monomer and dimer ofCH3-AD2-IgG-hRS7 (Additional file 1: Figure S1A; lane 5);
under reducing conditions, only three bands (Additional
file 1: Figure S1A; lane 3) were evident, which correspond
to the three constituents of (Rap)2-E1-(Rap)2, namely,
Rap-DDD2 (Additional file 1: Figure S1A; lane 1), and
the heavy (H) and light (L) chains from CH3-AD2-IgG-
hRS7 (Additional file 1: Figure S1A; lane 2), indicating
the absence of non-product proteins. SE-HPLC analyses
of (Rap)2-E1-(Rap)2, CH3-AD2-IgG-hRS7, and Rap-DDD2
revealed that each existed as a major peak with retention
times consistent with their calculated masses (Additional
file 1: Figure S1B). Dynamic light scattering analysis of
(Rap)2-E1-(Rap)2 showed an average diameter of 15.83 nm,
with a width of 6.36 nm (Additional file 1: Figure S1C).
Whereas the CK- and CH3-formats of DNL conjugates
displayed similar SE-HPLC profiles (Additional file 1:
Figure S1D, (Rap)2-E1*-(Rap)2 vs. (Rap)2-E1-(Rap)2), they
were distinguishable on reducing SDS-PAGE, with the
former having a faster moving H chain and a slower mov-
ing L chain (Additional file 1: Figure S1E, lane 2 vs. lane
4). The molecular purity of (Rap)2-22*-(Rap)2, as well as
that of (Rap)2-22-(Rap)2, was demonstrated also by redu-
cing SDS-PAGE in Additional file 1: Figure S1E in lanes 2
and 4, respectively, showing the presence of only three
bands in either lane. Further, the three bands in lane 2
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double bands of the H and L chains from CK-AD2-IgG-
hLL2 (lane 1). Likewise, the three bands in lane 4
matched the single band of Rap-DDD2 (lane 3) and the
two double bands of H and L chains from CH3-AD2-
IgG-hLL2 (lane 5).
Trop-2 expression on breast cancer cells
The cell surface expression of Trop-2 on a variety of hu-
man breast cancer cell lines was evaluated by flow cy-
tometry using hRS7 IgG as the primary antibody. Seven
cell lines were examined, including five basal-like, triple-
negative subtypes (MDA-MB-468, MDA-MB-231, BT-20,
HCC1806, and HCC1395), one luminal B, HER2-negative
subtype (MCF-7), and one HER2-positive subtype (SKBR-
3). HCC1395 was the only cell line found to be negative,
and MDA-MB-231 showed minimal expression (Median
fluorescence intensity, MFI = 10.37), while all other lines
had moderate (MFI = 40-100) to high (MFI = 100-400)
levels of Trop-2 (Additional file 2: Figure S2 and Additional
file 3: Table S1).
In vitro cytotoxicity
Based on the results of a 4-day MTS assay (Figure 2),
(Rap)2-E1-(Rap)2 exhibited subnanomolar to nanomolar
EC50 values for MDA-MB-468 (0.03 nM), MCF-7 (0.1
nM), BT-20 (0.18 nM), HCC1806 (0.19 nM), and SKBR-
3 (1.29 nM), all of which express moderate to high levels
of Trop-2. In comparison, (Rap)2-E1-(Rap)2 inhibited pro-
liferation of MDA-MB-231 (low Trop-2) or HCC1395
(negative Trop-2) only at higher concentrations (EC50 > 50
nM). In all cell lines tested, either module (CH3-AD2-
IgG-hRS7, Rap-DDD2) alone or the combination of theFigure 2 In vitro cytotoxity of (Rap)2-E1-(Rap)2 in selected breast canc
E1-(Rap)2, CH3-AD2-IgG-hRS7, Rap-DDD2, or a combination of hRS7 IgG and
with the MTS assay, and the results relative to untreated cells were plotted
(EC50) values were determined using non-linear regression sigmoidal dose–parental hRS7 IgG with Rap-DDD2 showed negligible
cytotoxicity. Besides breast cancer cell lines, potent cyto-
toxicity with subnanomolar EC50 values was observed for
(Rap)2-E1-(Rap)2 in Trop-2-expressing cell lines of other
cancers (Additional file 4: Figure S3), including prostate
cancer (MDA PCa 2b, PC-3), lung cancer (Calu-3), pan-
creatic cancer (BxPC-3), and cervical cancer (ME-180),
but not in Trop-2-negative cell lines, such as 22Rv1 (pros-
tate cancer). Further studies showed (Rap)2-E1-(Rap)2 to
be the most effective in inhibiting the proliferation of
MDA-MB-468 or BT-20 compared to other DNL-Rap
conjugates that do not target Trop-2 (Figure 3A). The
observed EC50 values from the current and previous
studies also indicate (Rap)2-E1-(Rap)2 to be considerably
more cytotoxic than Rap(Q)-hRS7 in HCC-1806 and
BT-20 (Figure 3B), as well as in MDA-MB-468, MCF-7
and SKBR-3 (Table 2). Moreover, the potency of (Rap)2-
E1*-(Rap)2, the CK-counterpart of (Rap)2-E1-(Rap)2, was
comparable to (Rap)2-E1-(Rap)2 in HCC-1806, but ap-
peared to be reduced in potency in MDA-MB-468
(Figure 3C).
Cell binding and internalization of (Rap)2-E1-(Rap)2
We compared the binding affinity of (Rap)2-E1-(Rap)2
with that of parental hRS7-IgG for MDA-MB-468 cells.
As shown in Figure 4A, (Rap)2-E1-(Rap)2 and hRS7-IgG
bound equivalently to MDA-MB-468 at all three concen-
trations examined, indicating the avidity of (Rap)2-E1-
(Rap)2 for Trop-2 is not compromised. We also examined
the intracellular distribution of (Rap)2-E1-(Rap)2 in MDA-
MB-468, and found it was effectively internalized at 37°C
after 2-h incubation, and existed mostly as punctas within
the cytoplasm (Figure 4B).er cell lines. Cells were cultured for 4 days in the presence of (Rap)2-
Rap-DDD2 at indicated concentrations. Viable cells were determined
against log of concentrations. Half maximal effective concentration
response curve of Prism software.
Figure 3 Selection of (Rap)2-E1-(Rap)2 for TNBC. The potency of (Rap)2-E1-(Rap)2 was compared: A, with five non-Trop-2-targeting DNL-Rap
conjugates in MDA-MB-468 and BT-20; B, with Rap(Q)-hRS7 in BT-20 and HCC1806; and C, with (Rap)2-E1*-(Rap)2 in HCC1806 and MDA-MB-468.
(Rap)2-C2–(Rap)2, (Rap)2-14-(Rap)2, (Rap)2-20-(Rap)2, (Rap)2-22-(Rap)2, and (Rap)2-74-(Rap)2 are five counterparts of (Rap)2-E1-(Rap)2, generated by
substituting hRS7 with humanized antibodies that targets HLA-DR, CEACAM5, CD20, CD22, and CD74, respectively.
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The toxicity of (Rap)2-E1-(Rap)2 to hematological cells
was assessed on human peripheral blood mononuclear
cells (PBMC) obtained from two healthy donors, follow-
ing treatment with (Rap)2-E1-(Rap)2 at 0.1, 1, and 10
nM for 18 h. Treatment with (Rap)2-E1-(Rap)2 had
nearly the same amount of apoptotic and dead cells as




(Rap)2-E1-(Rap)2 0.03 0.1 1.29
Rap(Q)-hRS7 3.8b >100b >100b
aHalf maximal effective concentration; bFrom previous results [34]; cNot determinedindicating that (Rap)2-E1-(Rap)2 is not toxic to PBMC at
concentrations up to 10 nM.
MTD in nude mice
Among the four groups (20, 40, 60 or 80 μg) tested, only
those mice that received the four injections of (Rap)2-
22*-(Rap)2 at 20 μg survived without acute toxicity or
death. One of the three animals lost ~12% of its body. Rap(Q)-hRS7
HCC1806 BT-20 MDA-MB-231 HCC1395
0.19 0.18 >50 ~100
10.1 >100 NDc NDc
.
Figure 4 (See legend on next page.)
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Figure 4 Evaluation of binding and internalization of (Rap)2-E1-(Rap)2 in MDA-MB-468. A, flow cytometric analyses showing equivalence in
binding of (Rap)2-E1-(Rap)2 and hRS7 IgG to MDA-MB-468 at three concentrations (1, 5 and 25 nM). The CD20-targeting (Rap)2-20-(Rap)2 and
hA20 served as negative controls; B, following incubation, pH 2.5 treatment, and fixation as described in the Methods, cells were stained with
GAH- Alexa Fluor 488 (green) to detect intracellular (Rap)2-E1-(Rap)2, and also with Hoechst 33258 (blue) and human transferrin-conjugated Alexa
Fluor 568 (red) to reveal the nucleus and endosomes, respectively.
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7 had regained much of this lost weight. All three mice
survived to the end of the study on day 56. The max-
imum tolerated dose (MTD) of a DNL-Rap conjugate
was therefore defined as 20 μg, administered i.v. every
four days for four times (q4dx4). Although we have not
formally determined the MTD of (Rap)2-E1*-(Rap)2 or
other DNL-Rap conjugates in similar studies, subsequent
experiments in tumor-bearing mice indicated that the
animals also tolerated (Rap)2-E1*-(Rap)2 or (Rap)2-20-
(Rap)2 when given the dosing regimen of 20 μg i.v.,
q4dx4.
In vivo activity
We selected (Rap)2-E1*-(Rap)2 for in vivo studies because
the CK-based conjugates exhibited superior Fc-effector
functions in vitro, as well as improved pharmacokinetics,
stability, and activity in vivo, as demonstrated for two
types of DNL conjugates having a similar structure to
IgG-Rap; namely, a bispecific hexavalent antibody com-
prising a pair of dimeric Fab linked to an IgG, and a
multivalent immunocytokine comprising a pair of dimeric
IFN-α linked to an IgG [35].
In the TNBC model of mice bearing MDA-MB-468 tu-
mors, all mice tolerated the two cycles of treatment with
no mouse losing more than 9% of starting body weight
during dosing (Additional file 6: Figure S5). Based on
area under the curve (AUC) determined on day 48,
(Rap)2-E1*-(Rap)2 significantly inhibited tumor growth
compared to the saline control (Figure 5A; P = 0.0254).
In addition, a significant survival benefit (Figure 5B), as
indicated by the median survival time, was obtained with
the (Rap)2-E1*-(Rap)2 group (98 days) when compared
to either the saline group (63 days; P < 0.0070) or the
(Rap)2-22*-(Rap)2 group (84 days; P < 0.0438). Notably, 2
of 8 mice in the (Rap)2-E1*-(Rap)2 group were tumor-
free when the experiment ended on day 105.
To further demonstrate the targeting specificity of
(Rap)2-E1*-(Rap)2 vs. (Rap)2-22*-(Rap)2, we performed
another study to compare their potency in a CD22-
expressing, but Trop-2-negative, tumor model. Mice
bearing disseminated Burkitt-NHL (Daudi) were treated
7 days after the animals were administered the cells to
ensure a large tumor-burden at the time of therapy
initiation (Figure 5C). All mice in the saline control
group succumbed to disease progression by day 32
(median = 32 days). Likewise, mice treated with theMTD of (Rap)2-E1*-(Rap)2 were all dead by day 48
(median = 36 days). Conversely, all mice that received the
MTD of (Rap)2-22*-(Rap)2 or half this dose were still alive
and tumor-free at the time the experiment was ended on
day 84. Overall, treatment with (Rap)2-22*-(Rap)2 resulted
in a significant survival benefit when compared to the sa-
line or treatment control (P < 0.0034).
Discussion
Rap is a promising antitumor toxin with several attract-
ive properties, including minimal toxicity, negligible im-
munogenicity, and the potential to overcome multiple
drug resistance via unusual mechanisms of internaliza-
tion and cytotoxicity. Over the years, we have made con-
siderable progress to enhance the potency of Rap by
targeting it to cancer cells expressing CD22, CD74 and
Trop-2, as exemplified by LL2-onconase [36], Rap-hLL1
[37], and Rap(Q)-hRS7 [34], respectively, but have also
encountered difficulty in scaled-up production of these
prototypes due to relatively low productivity of Rap-
hLL1 or Rap(Q)-hRS7 in mammalian cell cultures. We
believe the DNL™ platform technology, which conveni-
ently tethers four copies of Rap to the C-terminus of dif-
ferent IgG modules, has key production advantages for
Rap-based immunotoxins. Moreover, these DNL-Rap
conjugates ensure targeted delivery of Rap with signifi-
cantly improved potency in cancer cells expressing the
cognate antigens, as exemplified by (Rap)2-E1-(Rap)2 in
the current study with breast cancer cell lines. It is note-
worthy that in MDA-MB-468 cells with a moderate level
of Trop-2, the cytotoxicity of the DNL-generated (Rap)2-
E1-(Rap)2 (EC50 = 0.03 nM) was 100-fold more potent
than the recombinant Rap(Q)-hRS7 (EC50 = 3.8 nM),
and 3,000-fold more potent than unconjugated Rap
(EC50 > 100 nM). On the other hand, (Rap)2-E1-(Rap)2
inhibited the proliferation of Trop-2-negative HCC1395
cells only at much higher concentrations (EC50 > 50 nM)
and yet was not toxic to PBMCs, indicating the likely ex-
istence of a relatively large therapeutic window.
We reported previously that in MDA-MB-468 cells,
Rap(Q)-hRS7 co-localized with human transferrin in the
endosomes after a 2-h incubation at 37°C [34], whereas
in the current study under the same conditions, (Rap)2-
E1-(Rap)2 did not co-localize with human transferrin in
the endosomes, suggesting a different internalization
pathway, which may explain its greater potency in
MDA-MB-468 than observed for Rap(Q)-hRS7.
Figure 5 In vivo studies of DNL-Rap conjugates. (Rap)2-E1*-(Rap)2 was compared with (Rap)2-22*-(Rap)2 in a MDA-MB-468 xenograft model,
showing tumor growth in individual mice in A, and survival curves in B; (Rap)2-22*-(Rap)2 was compared with (Rap)2-E1*-(Rap)2 in a disseminated
Daudi model, showing survival curves in C.
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bodies, for which the CK-format was demonstrated to be
superior to the CH3-format [35], the potential advantage
of a CK-format of DNL-Rap vs. its CH3-counterpart is
not readily apparent from the present data, and will re-
quire further studies.
The potency and specificity of DNL-Rap conjugates
for targeted cancer therapy is also supported by the statis-
tically significant antitumor activity of (Rap)2-E1*-(Rap)2 in
suppressing growth of MDA-MB-468 xenografts, and by
the observed cure of all five mice with disseminated
Daudi lymphoma following treatment with four 20-μg
doses of (Rap)2-22*-(Rap)2 given 4 days apart, both of
which should reduce the potential concern that the lar-
ger size of DNL-Rap conjugates would negatively impact
their in vivo efficacy, particularly in solid cancer, due to
poor penetration.
Although hRS7 binds to selected human epithelial cells,
recent studies with a drug conjugate of hRS7 in cynomol-
gus monkeys, whose tissues cross-react with hRS7,
showed that tolerated doses occurred at clinically-relevant
concentrations, and that dose-limiting toxicities to normal
tissues were no different from those reported previously
with the free drug [38]. These data suggest that having
Rap attached to hRS7 may not add substantially itstoxicity to normal tissues, and that (Rap)2-E1-(Rap)2 or
(Rap)2-E1*-(Rap)2 may be tolerated at clinically-relevant
concentrations. In addition, because the structural motif
(x)D(y) identified to be responsible for the binding of ricin
A-chain or interleukin-2 to endothelial cells is absent in
the native sequence of Rap, and hRS7 is not cross-reactive
with human endothelial cells, we consider the likelihood
of (Rap)2-E1-(Rap)2 or (Rap)2-E1*-(Rap)2 causing vascular
leak syndrome as remote. Regarding the immunogenicity
of DNL-Rap conjugates, it needs to be addressed in a rele-
vant species as well as in future human studies.
Conclusions
We have generated a new class of immunoRNases and
demonstrated their potential for targeted therapy of can-
cer. These promising results warrant further studies to
advance the development of (Rap)2-E1-(Rap)2 or (Rap)2-
E1*-(Rap)2, in particular, and other DNL-Rap conjugates,
in general, as potential novel therapeutics for triple-
negative breast cancer or other Trop-2-expressing cancers.
Methods
Antibodies and reagents
Humanized antibodies including hA20 (anti-CD20, vel-
tuzumab), hLL2 (anti-CD22, epratuzumab), and hRS7
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anti-human IgG (FITC-GAH) was purchased from Jackson
ImmunoResearch Laboratories (West Grove, PA). Annexin
V Alexa Fluor 488 conjugate and 7-AAD were purchased
from Life Technologies Corporation (Grand Island, NY).
Expression and purification of DNL modules
To produce the Rap-DDD2 module used for DNL con-
jugation, a DNA fragment encoding Rap and a GGGGS
linker sequence was amplified by PCR from rPRL2#26
plasmid [34] and inserted into the MscI and XhoI re-
striction sites of the pET-26b vector to generate rap-GS-
pET26b. Subsequently, the DDD2 coding sequence was
amplified by PCR from IFNα2b-DDD2-pdHL2 [33] and
inserted into XhoI site of rap-pET26b to generate the
expression vector rap-GS-DDD2-pET26b. Competent
Rosetta-pLysS cells (EMD Millipore, Billerica, MA) were
transformed with rap-GS-DDD2-pET26b and cultured in
shaker flasks at 37°C in Difco 2xYT broth (Becton
Dickinson, Franklin Lakes, NJ), supplemented with 100
μg/mL kanamycin sulfate and 34 μg/mL chlorampheni-
col. When the cell density reached OD600 = 1.0, cultures
were switched to 30°C and protein expression was in-
duced with 0.4 mM IPTG for 4 h. Cell pellets were
frozen, thawed and homogenized in a lysis buffer com-
prising 2% Triton X-100, 5 mM MgSO4, 10 units/mL
benzonase (Novagen EMD Millipore), 100 μM 4-(2-ami-
noethyl) benzenesulfonyl fluoride (Sigma-Aldrich, St.
Louis, MO), and 20 mM Tris–HCl, pH 8.0. The insol-
uble material, containing inclusion bodies, was pelleted
by centrifugation, re-homogenized in 1% Triton X-100
in PBS, and re-pelleted. Inclusion bodies were solubi-
lized in 6 M guanidine-HCl, 100 mM Na-phosphate,
pH 8.0, and applied to a His-Select affinity column (GE
Healthcare, Piscataway, NJ). The denatured protein was
eluted in 4 M guanidine-HCl, 100 mM NaH2PO4,
pH 4.5. The eluate was neutralized with 3 M Tris–HCl,
pH 8.6, added dithioerythreitol (DTE) to 60 mM, and
held at room temperature overnight, to which was added
rapidly 10-fold volume of 0.5 M arginine, 20 mM oxi-
dized glutathione, 2 mM EDTA,100 mM Tris, pH 8.0,
followed by dialysis against 5 L of a renaturation buffer
(0.5 M arginine, 2 mM oxidized glutathione, 0.6 mM
DTE, 2 mM EDTA, 20 mM Tris, pH 8.0) for 72 h at 4°C,
and subsequently against PBS buffer.
Expression vectors for the CH3-AD2-IgG modules
were engineered from cognate IgG-pdHL2 expression
vectors, as described previously [39]. The CK-AD2-IgG
modules were generated by fusing AD2 and a hinge
linker sequence to the C-terminal end of the kappa light
chain [35]. These modules were produced in myeloma
cell culture of SpESFX-10 cells [40] and isolated from
culture broths using MabSelect affinity chromatography
(GE Healthcare).DNL conjugation
The Rap-DDD2 module was reacted with a CH3-AD2-IgG
or a CK-AD2-IgG of choice to generate a panel of DNL-
Rap conjugates, as listed in Table 1, with the structures of
the CH3- and CK-types shown schematically in Figure 1.
Typically, an AD2-IgG was combined with approximately
two mole-equivalents of Rap-DDD2, followed by the
addition of reduced glutathione to a final concentration of
2 mM. After incubation at room temperature overnight,
oxidized glutathione was added to a final concentration of
4 mM on the next day, the incubation continued for an-
other 24 h, and the resulting DNL-Rap conjugate was
purified by MabSelect affinity chromatography.
Molecular characterization of DNL-Rap conjugates
SDS-PAGE was performed under reducing and non-
reducing conditions using 4-20% Tris-Glycine gels
(Lonza, Allendale, NJ). SE-HPLC was performed at the
flow rate 1 ml/min and detection wavelength 280 nm
using an Alliance HPLC System with a BioSuite 250, 4-
μm UHR SEC column (Waters Corp. Milford, MA). Par-
ticle size analysis was performed by a contract laboratory
(Microtrac, Largo, FL).
Cell lines
All cell lines were purchased from the American Type
Culture Collection (ATCC, Manassas, VA), which in-
clude seven of breast cancer (MCF-7, MDA-MB-468,
MDA-MB-231, HCC1806, HCC1395, BT-20, SKBR-3),
three of prostate cancer (MDA PCa 2b, PC-3, 22Rv1),
one of pancreatic cancer (BxPC-3), one of lung cancer
(Calu-3), one of cervical cancer (ME-180), and one of
non-Hodgkin lymphoma (Daudi). Each cell line was
maintained according to the recommendations of ATCC
and routinely tested for mycoplasma using MycoAlert®
Mycoplasma Detection Kit (Lonza).
Internalization studies by fluorescence microscopy
MDA-MB-468 cells were placed at 3000 cells/well in 8-
well, Lab-Tek II chamber slides (Nalge Nunc Inter-
national) and incubated with 40 nM of (Rap)2-E1-(Rap)2
and 1:200 diluted human transferrin (hTf) conjugated to
Alexa Fluor 568 (T-23365, Life Technologies Corporation)
at 37°C for 2 h. After washing twice in PBS plus 2% BSA,
cells were treated in 0.1 M glycine buffer (pH 2.5) for
2 min, and then fixed in 4% formalin for 15 min, followed
by Alexa Fluor 488–conjugated goat anti-human IgG for
15 min. After washing twice with PBS, cells were stained
with Hoechst 33258 for 5 min and examined under a
fluorescence microscope.
Flow cytometry
Cells were trypsinized briefly, washed, re-suspended in
1% BSA-PBS, incubated with hRS7 or hA20 IgG, and
Liu et al. Molecular Cancer 2014, 13:53 Page 10 of 12
http://www.molecular-cancer.com/content/13/1/53detected with FITC-GAH. All incubations were 45 min
at 4°C with 1% BSA-PBS washes between incubations.
Cell binding was measured by flow cytometry using a
BD FACSCalibur (BD Biosciences, San Jose, CA).
In vitro proliferation
Cells were seeded in 96-well plates at 1,000-2,000 cells/
well and held at 37°C overnight prior to incubation with
the indicated agents for 4 days. Viable cells were mea-
sured using MTS substrate Cell Titer96® AQueous One
Solution (Promega, Madison, WI).
Toxicity in human PBMC
Buffy coats from healthy donors were purchased from
the Blood Center of New Jersey, with approval by the
New England Institutional Review Board. PBMCs were
isolated from buffy coats by standard density-gradient
centrifugation over Ficoll-Paque, and treated with (Rap)2-
E1-(Rap)2 at 37°C in 5% CO2 for 16 h. After incubation,
the cells were stained with Alexa Fluor® 488-labeled
annexin V, then with 7-aminoactinomycin-D, and ana-
lyzed by flow cytometry.
Determination of maximal tolerated dose (MTD) in mice
Female athymic nude mice (8 weeks old) were divided
into four groups of three each, with each group receiving
(Rap)2-22*-(Rap)2 at one of four different doses (20, 40,
60 or 80 μg). Animals were dosed i.v. every four days for
a total of four injections (q4dx4). Toxicity was assessed
by daily observations and weights taken twice weekly.
Mice were deemed to have lethal toxicity if they lost
more than 15% of starting body weight or were other-
wise deemed moribund. The MTD was the highest dose
administered in which all the mice in the group survived
the injections.
In vivo therapeutic activity
All animal studies were approved by the University of
Medicine and Dentistry of New Jersey’s Institutional
Animal Care and Use Committee (IACUC) and per-
formed in accordance with the Association for Assess-
ment and Accreditation of Laboratory Animal Care, U.S.
Department of Agriculture, and Department of Health
and Human Services regulations. Female NCr athymic
nude (nu/nu) mice, 5 weeks old, and SCID mice, 7 weeks
old, were purchased from Taconic Farms (Hudson, NY).
Two tumor models, solid and liquid cancers, were used
to evaluate the efficacy and specificity of DNL-generated
immunoRNases, (Rap)2-E1*-(Rap)2 and (Rap)2-22*-(Rap)2,
as binding and nonbinding agents for MDA-MB-468 and
vice versa for Daudi, respectively. For the MDA-MB-468
xenograft model, nude mice were each injected s.c. in the
flank with 200 μL of MDA-MB-468 cells (1 × 107) mixed
1:1 with matrigel (BD Bioscience). Once tumors reachedapproximately 0.2 cm3 in size, the animals were divided
into three groups of 8 to 9 each. The treatment group
received i.v. administration of the MTD of (Rap)2-E1*-
(Rap)2 (20 μg i.v. q4dx4), followed by a second cycle
24 days after the last injection of the first cycle. The con-
trol group received the same dose/schedule of a CD22-
targeting (Rap)2-22*-(Rap)2, which served as an alternative
non-specific counterpart of (Rap)2-E1*-(Rap)2. The third
group remained untreated and only received saline (100 μl).
After treatment commenced, mice were weighed and tu-
mors measured weekly. For both models, tumor volume
(TV) was determined by measurements in two dimen-
sions using calipers, with volumes defined as: L × w2/2,
where L is the longest dimension of the tumor and w the
shortest. When a tumor in individual mice ulcerated or
exceeded 1.0 cm3 in measured volume, the animal was
deemed to have succumbed to disease progression and
was euthanized.
The model for disseminating human Burkitt lymph-
oma was established by injecting SCID mice i.v. with
1.5×107 Daudi cells. On the day cells were administered,
the mice were randomized into groups of 5 each. Ther-
apy began 7 days later. The treatment groups received
(Rap)2-22*-(Rap)2 at either the MTD (20 μg, q4dx4) or
at half that dose (10 μg q4dx4). For the three controls,
one group received the same amount of (Rap)2-E1*-
(Rap)2, another group received the parental hLL2 IgG/
epratuzumab (25 μg, q4dx4), and the third group received
only saline (100 μL). Mice were deemed to have suc-
cumbed to disease progression when hind-limb paralysis
developed, or if they lost more than 15% of their initial
body weight, or if they became otherwise moribund.
Statistical analysis for the tumor growth data was based
on AUC as well as survival time. The profile of tumor
growth in each mouse was obtained through linear curve
modeling. As a consequence of incompleteness of some
of the growth curves (due to deaths), statistical compari-
sons of AUC was only performed up to the time at which
the first animal within a group was euthanized due to
disease progression. An f-test was employed to determine
equality of variance between groups prior to statistical
analysis of growth curves. A two-tailed t-test was used to
assess statistical significance (P ≤ 0.05) between treatment
groups except for the saline control in which a one-tailed
t-test was utilized. Survival studies were analyzed from
Kaplan-Meier plots (log-rank analysis), using the Prism
GraphPad Software (v4.03) software package (Advanced
Graphics Software, Rancho Santa Fe, CA).
Additional files
Additional file 1: Figure S1. Molecular characterization of selected
DNL-Rap conjugates. A. Reducing (lanes 1–3) and non-reducing (lanes 4–6)
SDS-PAGE analyses of Rap-DDD2 (lanes 1 and 4), CH3-AD2-IgG-hRS7 (lanes 2
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http://www.molecular-cancer.com/content/13/1/53and 5), and (Rap)2-E1-(Rap)2 (lanes 3 and 6). B. SE-HPLC profiles of (Rap)2-E1-
(Rap)2, CH3-AD2-IgG-hRS7 (denoted as hRS7-IgG-AD2) and Rap-DDD2.
C. Dynamic light scattering analysis of (Rap)2-E1-(Rap)2. D. SE-HPLC profiles of
(Rap)2-E1*-(Rap)2 and (Rap)2-E1-(Rap)2. E. SDS-PAGE analyses of CK-AD2-IgG-
hLL2, (Rap)2-22*-(Rap)2, Rap-DDD2, (Rap)2-22-(Rap)2, and CH3-AD2-IgG-hLL2.
Additional file 2: Figure S2. Trop-2 expression in selected breast
cancer cell lines as determined by binding to hRS7. Cells were incubated
without or with 10 μg/mL of hRS7 or hA20 IgG on ice for 45 min,
followed by FITC labeled goat anti-human IgG (GAH-FITC), and analyzed
by flow cytometry. Data were processed by FlowJo software, with the
MFI shown in Additional file 3: Table S1.
Additional file 3: Table S1. Surface Trop-2 expression on selective
breast cancer cell lines as determined by binding to hRS7.
Additional file 4: Figure S3. In vitro cytotoxicity of (Rap)2-E1-(Rap)2
against a variety of solid cancer lines. Cells were harvested, plated into
96-well plates, and incubated with (Rap)2-E1-(Rap)2 at a final concentration
ranging from 100 to 1 × 10−6 nM or 66.7 to 6.67×10−7 nM for a period of
four doubling times, which were predetermined to be 7, 5, 5, 8, 5, and 6 days
for MDA PCa 2b, PC-3, 22Rv1, Calu-3, BxPC-3, and ME-180, respectively. After
each incubation period, MTS substrate (Cell Titer 96® AQueous One Solution;
Promega) was added to all the wells and the color developed was
measured at 1-h intervals for up to 4 h. Activity of test agents was calculated
as a percent viability of treated cells relative to untreated cells using
Microsoft Excel and Prism software (X = log [X]; non-linear regression
sigmoidal dose response curves). As controls, cells were treated similarly
with (Rap)2-22-(Rap)2, hRS7 IgG alone, or a combination of hRS7 IgG with
either recombinant Rap (rRap, Ref. [36]) or Rap-DDD2. The EC50 values of
(Rap)2-E1-(Rap)2 were determined to be 0.005, 0.04, 0.307, 0.032, 0.522, and
>100 nM for MDA PCa 2b, PC-3, BxPC-3, ME-180, Calu-3, and 22Rv1,
respectively.
Additional file 5: Figure S4. Effect of (Rap)2-E1-(Rap)2 on hematological
cells. Minimal toxicity of (Rap)2-E1-(Rap)2 to PBMCs from two healthy
donors was indicated by comparable viable and apoptotic cells with
those of untreated controls.
Additional file 6: Figure S5. Tolerability of mice treated with two cycles
of (Rap)2-E1*-(Rap)2 or (Rap)2-22*-(Rap)2 at MTD as assessed by the
percent of starting body weight.
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